Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population. (December 2016) - Fischer, M.; Wulff, B.; Baruchel, S.; Berlanga, P.; Trahair, T.; Mechinaud, F.; Schulte, J.; Modak, S.; Merks, J.H.; Zwaan, C.M.; Marshall, L.V.; Casanova, M.; et al.